PROTECTED HEALTH INFORMATION (PHI) AND INSTITUTIONAL REVIEW BOARD (IRB) APPLICATIONS

To see a definition of PHI, visit https://bit.ly/2HMBBbT

Where will your study obtain PHI from?

where will your study obtain Phi Irom:				
	From a Purdue Covered Component	Directly from a Healthcare Provider or other HIPAA Covered Entity	Directly from a study participant in the human subjects research	Fully de-identified from a repository, biobank, or databank
What permissions will I need to show the IRB for review of my application?	 Permission via the Purdue Covered Component to access PHI. Please see www.purdue.edu/hipaa to connect with the Purdue Covered Component's access procedures. 	 Contact the Provider's HIPAA privacy department to obtain permission to access their PHI. Researchers must obtain written permission from the HIPAA Privacy Officer at each study site. 	 Participant should give permission to send you this information directly. The participant may need to work with their HIPAA-covered provider to obtain PHI necessary for the study. 	 Contact the provider to determine the process that must occur for access to the de-identified data. This may include contracts or terms required by the repository. Contracts or Data Use/Access Agreements for datasets must be signed by SPS Contracting. Contact spscontr@purdue.edu to begin the process.
What do I need to include in the IRB application materials?	 A draft of the Purdue Authorization for Release of PHI. You must include a draft that details the reason for disclosure, personnel, and specific medical records for each study. If you request a waiver of this authorization, you must provide specific justification to the IRB. See the IRB application narrative form for the criteria required for these requests. 	 Include a statement in all consent forms to notify participants that participation in the study requires separate release of PHI from the Covered Entity. A description of the process required to access PHI from the Provider written into the application. Write a detailed description of the process required to access PHI from the Provider. 	 A description of how data are transferred (i.e. paper, electronic) from the participant to the researcher. This process must appear in the application. A statement in all consent forms to notify participants that release of their PHI is [required] or [optional] for particiption in the study. 	 Information about any links to identifiers, direct or indirect that may be exchanged. Explain the process that must take place to access the data or samples. You will not need to draft a consent form for repository/biobank data.

Research records utilizing PHI must be retained for six years following study closure.